Disease-specific quality of life in patients with lupus nephritis

Jolly M., Toloza S., Goker B., Clarke A. E. , Navarra S. V. , Wallace D., ...More

LUPUS, vol.27, no.2, pp.257-264, 2018 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 27 Issue: 2
  • Publication Date: 2018
  • Doi Number: 10.1177/0961203317717082
  • Journal Name: LUPUS
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.257-264
  • Keywords: Systemic lupus erythematosus, lupus nephritis, quality of life, LupusPRO, ERYTHEMATOSUS, SLE, CYCLOPHOSPHAMIDE, MORTALITY, MOFETIL, THERAPY, TRIAL


Background Patient-reported outcomes in lupus nephritis (LN) are not well studied. Studies with disease-targeted PRO tool in LN do not exist. Herein, we describe quality of life (QOL: HRQOL & non-HRQOL) among LN patients using LupusPRO.